Medilink EM works with life science businesses, academic institutions and the NHS across the East Midlands, to help new and existing life science companies to develop and grow.
In addition to the business support programmes it helps to deliver, Medilink EM provides a range of valuable benefits for its members, including profile-raising, special offers from Medilink EM Patrons, discounts on exhibition stands and event offers and discounts.
Medilink EM Patronage is offered to organisations because of their prominence within the East Midlands and their recognition of the importance of life sciences in the region. Patrons also appreciate the positive contribution that Medilink EM makes to the sector through its business support activities.
Please see below for a spotlight on the work of Medilink EM Patron, Morningside Pharmaceuticals.
Morningside Pharmaceuticals
Morningside Pharmaceuticals Ltd is an established manufacturer, supplier and exporter of generic and branded medicines. With a service offering of over 28 years, they have become a trusted name in the pharmaceutical industry. The Morningside companies, based in Leicestershire, are also leading innovators of new generic medicines with a strong emphasis on patients’ needs.
Markets
With 230 licensed generic and branded medicines in the UK and the EU, Morningside distributes twice daily to NHS hospitals and pharmacies.
Globally, they are one of the leading suppliers of a wide range of quality medicines to aid agencies, charities and NGOs. This includes UNICEF, the Red Cross, the World Health Organisation (WHO) and Medicines San Frontier (MSF). Since inception, the company has exported to more than 120 countries around the world.
Morningside’s export success has been recognised by many awards including the UK’s most prestigious accolade – the Queen’s Award for Enterprise: International Trade 2012.
Key Therapeutic Areas:
• Cardiology
• Endocrinology
• Gastroenterology
• Gynaecology
• HIV & Tuberculosis
• Immunology
• Neurology
• Oncology
• Rheumatology
Innovation
Morningside’s innovative approach embraces challenges with heavy investment, including Research & Development and launching new niche generic molecules, resulting in greater choice for both pharmacists and patients.
Several examples of niche products launched by Morningside include:
• Levest: 1st generic contraceptive launched in the UK (Contraceptive)
• Glycopyrronium Bromide: Previously a ‘special unlicensed drug’ (Hyper Salivation)
• Metformin SR: All slow-release, enabling patients to reduce the number of tablets taken (Diabetes)
• Prescription Sodium Fluoride Toothpaste: 1st generic Prescription Only Medicine (POM) in the UK for severe Gingivitis (Dental Health)
• Diclofenac Mouthwash: Enables patients to use a mouthwash rather than swallowing tablets (Mouth Inflammation)
• Liothyronine Sodium: 1st to launch the 5 & 10mcg strengths with extended shelf life, offering greater choice to patients (Thyroid)
• Prochlorperazine Maleate Buccal Tablets: innovated to dissolve in the mouth (Nausea and Vomiting)
Morningside manages the entire end-to-end process from research & development to registration, to sales, marketing and export.
Company Successes
Over its long and illustrious history, Morningside has gone from strength to strength. Several recent company successes include:
• Morningside’s Chief Executive, Dr Nik Kotecha OBE, was named the Lloyds Bank National Business Awards Entrepreneur of the Year 2019. In the same year, Dr Kotecha was named the Nat West Great British Entrepreneur Awards’ national Innovation Entrepreneur of the Year.
• Board of Trade Award received from former Secretary of State for International Trade, Dr Liam Fox (2018)
• The Leicester Arena is renamed the Morningside Arena, as part of a major naming-rights deal, which also saw local charities gifted fundraising space for free, as part of the partnership.
• Winning the Innovation in Generics Award at the Pharmacy Business Awards 2017
• In 2016 Dr Kotecha was invited to join Prime Minister, Theresa May, on her first trade visit to India. He was among 30 captains of industry on the three-day visit to Delhi and Mumbai, in order to drum up business and help negotiate a post-Brexit trade agreement. Following the trip £1.2 billion in trade deals were announced.
More information on Medilink EM Patronage is available here
More information on Morningside is available here
